Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Buy
61
DNTH Quote, Financials, Valuation and Earnings
Last price:
$44.26
Seasonality move
:
24.02%
Day range:
$43.61 - $45.08
52-week range:
$13.37 - $45.46
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
519.25x
P/B ratio:
3.47x
Volume:
431K
Avg. volume:
684.6K
1-year change:
87.07%
Market cap:
$1.9B
Revenue:
$6.2M
EPS (TTM):
-$3.49
Analysts' Opinion
-
Consensus RatingDianthus Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $63.05, Dianthus Therapeutics, Inc. has an estimated upside of 42.45% from its current price of $44.26.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $46.00 representing 100% downside risk from its current price of $44.26.
Fair Value
-
According to the consensus of 12 analysts, Dianthus Therapeutics, Inc. has 42.45% upside to fair value with a price target of $63.05 per share.
DNTH vs. S&P 500
-
Over the past 5 trading days, Dianthus Therapeutics, Inc. has overperformed the S&P 500 by 0.32% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Dianthus Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Dianthus Therapeutics, Inc. revenues have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Dianthus Therapeutics, Inc. reported revenues of $396K.
Earnings Growth
-
Dianthus Therapeutics, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Dianthus Therapeutics, Inc. reported earnings per share of -$0.97.
Enterprise value:
1.5B
EV / Invested capital:
2.73x
Price / LTM sales:
519.25x
EV / EBIT:
--
EV / Revenue:
486.15x
PEG ratio (5yr expected):
-0.32x
EV / Free cash flow:
-13.65x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$2.7M
Return On Assets:
-31.9%
Net Income Margin (TTM):
-4104.78%
Return On Equity:
-33.81%
Return On Invested Capital:
-33.7%
Operating Margin:
-10173.74%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $3.5M | $5.4M | $3.1M | $2.2M | $396K | |
| Gross Profit | $3.3M | $4.9M | $2.7M | $2.1M | $297K | |
| Operating Income | -$45.9M | -$82.9M | -$140.3M | -$29.9M | -$40.3M | |
| EBITDA | -$45.7M | -$82.5M | -$139.9M | -$29.8M | -$40.2M | |
| Diluted EPS | -$157.75 | -$2.50 | -$3.49 | -$0.74 | -$0.97 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $196.5M | $132.1M | $191.5M | $287.5M | $413.8M | |
| Total Assets | $206.2M | $164.1M | $192.5M | $354.2M | $577.4M | |
| Current Liabilities | $10.1M | $12.9M | $13.1M | $15.7M | $23.9M | |
| Total Liabilities | $16.5M | $40.1M | $14.1M | $16.4M | $31M | |
| Total Equity | $189.7M | $124M | $178.4M | $337.9M | $546.5M | |
| Total Debt | -- | $27.2M | $257K | -- | $1.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$33.9M | -$62.6M | -$109.5M | -$21.3M | -$30.6M | |
| Cash From Investing | $15.8M | -$271.9M | -$183.1M | -$259.4M | -$201.3M | |
| Cash From Financing | $138.4M | $211.1M | $314.9M | $296K | $274.5M | |
| Free Cash Flow | -$34M | -$62.7M | -$109.6M | -$21.3M | -$30.6M | |
DNTH
Sector
Market Cap
$1.9B
$28.5M
Price % of 52-Week High
97.37%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-18.69%
-1.33%
1-Year Price Total Return
87.07%
-20.32%
Beta (5-Year)
1.558
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$43.82
200-day SMA
Buy
Level
$25.66
Bollinger Bands (100)
Buy
Level
23.86 - 39.86
Chaikin Money Flow
Buy
Level
4.6M
20-day SMA
Buy
Level
$41.15
Relative Strength Index (RSI14)
Buy
Level
65.70
ADX Line
Buy
Level
37.03
Williams %R
Neutral
Level
-20.8588
50-day SMA
Buy
Level
$37.56
MACD (12, 26)
Buy
Level
2.25
25-day Aroon Oscillator
Buy
Level
88
On Balance Volume
Neutral
Level
12.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (18.0128)
Buy
CA Score
(Annual)
Level (-0.0881)
Sell
Beneish M-Score
(Annual)
Level (-0.0656)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (4.9857)
Buy
Piotroski F Score
(Annual)
Level (5)
Sell
Quality Ratio Score
Level (3)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.
Stock Forecast FAQ
In the current month, DNTH has received 12 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DNTH average analyst price target in the past 3 months is $63.05.
-
Where Will Dianthus Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Dianthus Therapeutics, Inc. share price will rise to $63.05 per share over the next 12 months.
-
What Do Analysts Say About Dianthus Therapeutics, Inc.?
Analysts are divided on their view about Dianthus Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Dianthus Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $46.00.
-
What Is Dianthus Therapeutics, Inc.'s Price Target?
The price target for Dianthus Therapeutics, Inc. over the next 1-year time period is forecast to be $63.05 according to 12 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DNTH A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Dianthus Therapeutics, Inc. is a Buy. 12 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DNTH?
You can purchase shares of Dianthus Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Dianthus Therapeutics, Inc. shares.
-
What Is The Dianthus Therapeutics, Inc. Share Price Today?
Dianthus Therapeutics, Inc. was last trading at $44.26 per share. This represents the most recent stock quote for Dianthus Therapeutics, Inc.. Yesterday, Dianthus Therapeutics, Inc. closed at $44.26 per share.
-
How To Buy Dianthus Therapeutics, Inc. Stock Online?
In order to purchase Dianthus Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get DNTH Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DNTH
Sector
P/E ratio
--
23.75x
PEG ratio
-0.32x
-0.01x
P/B ratio
3.47x
1.83x
Price / LTM sales
519.25x
1.60x
Growth Metrics
DNTH
Sector
Revenue growth
-81.77%
4.85%
Earnings growth
-32.3%
11.11%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.90
-$0.20
Profitability
DNTH
Sector
Profitability FY 2024
$5.8M
$3.6M
Return on invested capital
-33.7%
-30.98%
Return on assets
-31.9%
-27.62%
Return on equity
-33.81%
-36.69%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
10
Estimated Next Earnings Date
Feb
4
Balance Sheet
DNTH
Sector
Total cash
$402.6M
$27.2M
Short term investments
$252.4M
$25.7M
Total assets
$374.2M
$79.7M
Long term debt
$1.1M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
